Processa Pharmaceuticals, Inc. Operating Lease Liability
Processa Pharmaceuticals, Inc. (PCSA) had Operating Lease Liability of $21.83 thousand as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2025-08-07
- 2025-06-30: Operating Lease, Liability $21.83K.
- 2025-03-31: Operating Lease, Liability $44.59K.
- 2024-12-31: Operating Lease, Liability $66.91K.
- 2024-09-30: Operating Lease, Liability $88.78K.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-06-30 | $21.83K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $44.59K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $66.91K 10-K · filed 2025-03-20 |
| 2024-09-30 | $88.78K 10-Q · filed 2024-10-30 |
| 2024-06-30 | $109.33K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $129.47K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $150.55K 10-K · filed 2024-03-29 |
| 2023-09-30 | $171.52K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $191.22K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $210.52K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $229.45K 10-K · filed 2023-03-30 |
| 2022-09-30 | $247.97K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $31.21K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $55.27K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $78.46K 10-K · filed 2022-03-30 |
| 2021-09-30 | $101.54K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $123.34K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $144.71K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $165.66K 10-K · filed 2021-03-25 |
| 2020-09-30 | $166.50K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $186.56K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $206.16K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $225.38K 10-K · filed 2020-03-06 |
| 2019-09-30 | $244.16K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $264.22K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $283.88K 10-Q · filed 2019-05-14 |
| 2019-01-02 | $303.16K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |